Bio + Health

Investing in Telepatia

Daisy Wolf, Gabriel Vasquez, and Eva Steinman Posted June 17, 2026

Nicolás Abad’s father was the kind of doctor patients never forget.

A physician in Colombia, he became known as “Telepatia” because of his uncanny ability to understand what was wrong before patients had even finished explaining their symptoms.

He died at 58 from a preventable drug interaction – just days before the release of ChatGPT, which helped usher in a new generation of AI capable of catching this type of risk.

Today, Nico is building the product that could have helped save his father’s life, and that his father would have loved as a doctor.

We’re excited to announce our lead investment in Telepatia’s $33 million Series A.

Latin America has 700 million people, but a severe shortage of clinicians. The region has 43% fewer physicians and 65% fewer nurses per capita than OECD countries on average. Where the United States has spent decades piling software on top of a fractured system and created a new kind of mess, Latin America has the advantage of starting from a clean slate, and the potential to leapfrog the clinician shortage entirely.

Telepatia is building the AI-native clinical platform for Latin America. Its platform combines AI documentation, clinical decision support, and a growing suite of AI healthcare employees—including AI doctors, nurses, and auditors—integrated across hospital systems and trained on clinical guidelines, peer-reviewed literature, and local institutional protocols.

Since launching in July 2025, the platform has deployed across 25+ hospital systems in Brazil, Colombia, and Mexico, reaching 14 million patients. Doctors use it all day. Protocol adherence has risen from 84% to 99% after deployment with physicians recovering 1.7 hours daily – time they now spend with patients. Telepatia has already prevented 60,000 medical errors in real time, allowing physicians to adjust course immediately.

Take it from the customers themselves. “The real test of any clinical tool is whether doctors actually use it,” says José Henrique Dias Salvador, CEO of Mater Dei in Brazil. “Our physicians use Telepatia eight hours a day. We’ve never seen adoption like that.”

The top 100 health institutions in Latin America employ 50% of physicians. This concentration means that a single platform can achieve outsized distribution once it breaks into the top systems. Win the right logos, and distribution compounds in ways that simply aren’t possible in more saturated markets. Telepatia is achieving this.

We are joined in this round by Palantir CTO Shyam Sankar, Rappi founder Simón Borrero, and Nubank founder David Vélez, three leaders who have built and scaled transformative technology in complex industries across Latin America and the world.

Nico’s father had a wall covered with portraits of Nobel laureates he admired – scientists like Allvar Gullstrand and Richard Feynman whose discoveries changed the course of medicine and science.

We asked Nico what winning a Nobel Prize would feel like. He said: earning a place on that wall.

Nico’s goal is to win the first Nobel Prize in Medicine awarded to a Latin American since 1984. As he puts it, “Recent Nobel Prizes in Physics and Chemistry have gone to breakthroughs powered by AI. We believe Medicine is next.”

About the Contributors
Want More a16z Bio + Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future.

Learn More
Recommended For You
Enterprise

new Investing in Convey

Joe Schmidt and Olivia Moore
Enterprise

Investing in Town

Alex Rampell and Justine Moore
Enterprise

Investing in Lassie

Alex Rampell and Olivia Moore
American Dynamism

Investing in Westmag

Erin Price-Wright and Oliver Hsu
Enterprise

Investing in Endra

Joe Schmidt, David Haber, Caroline Goggins, and Zabie Elmgren

Want More Bio+Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future.

Sign Up On Substack

Views expressed in “posts” (including podcasts, videos, and social media) are those of the individual a16z personnel quoted therein and are not the views of a16z Capital Management, L.L.C. (“a16z”) or its respective affiliates. a16z Capital Management is an investment adviser registered with the Securities and Exchange Commission. Registration as an investment adviser does not imply any special skill or training. The posts are not directed to any investors or potential investors, and do not constitute an offer to sell — or a solicitation of an offer to buy — any securities, and may not be used or relied upon in evaluating the merits of any investment.

The contents in here — and available on any associated distribution platforms and any public a16z online social media accounts, platforms, and sites (collectively, “content distribution outlets”) — should not be construed as or relied upon in any manner as investment, legal, tax, or other advice. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment. Any projections, estimates, forecasts, targets, prospects and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Any charts provided here or on a16z content distribution outlets are for informational purposes only, and should not be relied upon when making any investment decision. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, posts may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein. All content speaks only as of the date indicated.

Under no circumstances should any posts or other information provided on this website — or on associated content distribution outlets — be construed as an offer soliciting the purchase or sale of any security or interest in any pooled investment vehicle sponsored, discussed, or mentioned by a16z personnel. Nor should it be construed as an offer to provide investment advisory services; an offer to invest in an a16z-managed pooled investment vehicle will be made separately and only by means of the confidential offering documents of the specific pooled investment vehicles — which should be read in their entirety, and only to those who, among other requirements, meet certain qualifications under federal securities laws. Such investors, defined as accredited investors and qualified purchasers, are generally deemed capable of evaluating the merits and risks of prospective investments and financial matters.

There can be no assurances that a16z’s investment objectives will be achieved or investment strategies will be successful. Any investment in a vehicle managed by a16z involves a high degree of risk including the risk that the entire amount invested is lost. Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by a16z is available here: https://a16z.com/investments/. Past results of a16z’s investments, pooled investment vehicles, or investment strategies are not necessarily indicative of future results. Excluded from this list are investments (and certain publicly traded cryptocurrencies/ digital assets) for which the issuer has not provided permission for a16z to disclose publicly. As for its investments in any cryptocurrency or token project, a16z is acting in its own financial interest, not necessarily in the interests of other token holders. a16z has no special role in any of these projects or power over their management. a16z does not undertake to continue to have any involvement in these projects other than as an investor and token holder, and other token holders should not expect that it will or rely on it to have any particular involvement.

With respect to funds managed by a16z that are registered in Japan, a16z will provide to any member of the Japanese public a copy of such documents as are required to be made publicly available pursuant to Article 63 of the Financial Instruments and Exchange Act of Japan. Please contact compliance@a16z.com to request such documents.

For other site terms of use, please go here. Additional important information about a16z, including our Form ADV Part 2A Brochure, is available at the SEC’s website: http://www.adviserinfo.sec.gov.